Clinical Trials Logo

Filter by:
NCT ID: NCT02936362 Completed - Clinical trials for Dietary Modification

Testing the Effect of Whole-wheat Sourdough Bread Compared to White Bread on Healthy Individuals

Start date: February 2016
Phase: N/A
Study type: Interventional

Bread is the most common grain product in the world, with consumption surpassing 3 billion individuals per year. Sourdough whole-grain bread is considered a healthy alternative to white, refined-wheat bread. This cross-over study will test the effect of consumption of sourdough bread compared to white bread following a short dietary intervention period (one week) on multiple clinical parameters and gut microbiota.

NCT ID: NCT02936102 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Start date: October 20, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or in combination with PDR001 in adult patients with advanced solid tumors. By blocking the interaction between Programmed Death Ligand-1 (PD-L1) and its receptors, Programmed Death-1 (PD-1) and B7.1, FAZ053 inhibits the PD-L1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells. This study has been designed as a Phase I, open-label, multi-center study with a dose escalation part of FAZ053 as single agent and in combination with PDR001, followed by a dose expansion part of FAZ053 as single agent. FAZ053 will initially be dosed every three weeks. A less frequent dosing regimen such as every 6 weeks may be evaluated in parallel. A patient may continue treatment with FAZ053 single agent or in combination with PDR001 until the patient experiences unacceptable toxicity, confirmed disease progression per immune related Response Criteria and/or treatment is discontinued at the discretion of the investigator or the patient.

NCT ID: NCT02935634 Completed - Clinical trials for Advanced Gastric Cancer

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

FRACTION-GC
Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

NCT ID: NCT02935517 Active, not recruiting - Achromatopsia Clinical Trials

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Start date: August 3, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

NCT ID: NCT02934776 Enrolling by invitation - Clinical trials for Magnetic Resonance Imaging

Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer

Start date: August 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to examine if investigators can improve diagnosis of prostate cancer by using MRI/DTI?

NCT ID: NCT02932410 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

TOMORROW
Start date: October 24, 2017
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).

NCT ID: NCT02931032 Enrolling by invitation - Periodontitis Clinical Trials

Diagnosis of Common Oral Diseases by Signature Volatile Profiles

Start date: November 2016
Phase: N/A
Study type: Interventional

Oral diseases tend to be exacerbated due to delayed diagnosis. Patients avoid visiting their dentist even for regular checkups, and develop late stage disease, jeopardizing the treatment outcome. There is an urgent need for an inexpensive and minimally invasive technology that would serve as a diagnostic aid, allowing 1) efficient early detection and 2) treatment customization. Diagnostic modalities based on the detection of volatile organic compounds in the exhaled air may answer this need. The proposed research aims at investigating signature molecular patterns of common oral diseases, as a first step toward the development of a computerized non-invasive diagnostic breath test, based on the "Na-Nose" device. The proposed research will be divided to three distinct stages. Stages 1-2 will serve for the detection and analysis of Volatile Organic Compounds connected with common oral diseases, and for the characterization of a specified diagnostic nano-receptor array. Stage 3 will serve for the clinical testing of the array and as a proof of concept. In a pilot experiment, headspaces above colonies of S.mutans, S.sanguis, P.gingivalis and F.nucleatum were trapped and analyzed using Gas Chromatography Mass Spectrometry (GC-MS). A unique VOC signature, consisting of 20-35 molecules, was detected for each of the bacterial strains. These promising results allow the development of an algorithm for statistical detection of oral diseases by their VOC profile alone. Bacteria and distressed tissues emit unique VOCs, and additional research is required with other types and strains of bacteria - including cultivation of samples from active periodontal and carious lesions. The results of the proposed research may be revolutionary. A simple and non-invasive air sampling at home or in a drugstore will significantly increase patient compliance and curability rates, and decrease healthcare expenditure.

NCT ID: NCT02931006 Not yet recruiting - Clinical trials for Gonadotrophin and Sex Hormone Changes

Influence of Bovine Milk Consumption on Hormonal Profile in Males

Start date: January 2017
Phase: N/A
Study type: Interventional

50 men will be recruited to this study. Participants will be asked to ingest commercially available bovine milk. Hormonal profile will be analyzed before and after consumption.

NCT ID: NCT02930720 Recruiting - Healthy Clinical Trials

Pelvic Floor Displacement in Women With SUI and Healthy Women: An Ultrasound Study (Stress Urinary Incontinence)

SUI
Start date: October 2016
Phase: N/A
Study type: Observational

Pelvic floor main role is to maintain continence. pelvic floor malfunction could lead to urinary incontinence (UI). The known prevalence of UI among women is 25%-72%, in about 25%-50% it is Stress Urinary Incontinence (SUI), SUI prevalence changes with age and obstetric history. SUI is the complaint of involuntary leakage on activities which involves inter abdominal pressure rase, such as effort or exertion, or sneezing or coughing. pelvic floor movement is coordinated with the diaphragm, it moves caudally while inhaling and cranially while exhaling. it was shown that cranial sagittal displacement of the pelvic floor is correlated to pelvic floor normal and efficient function. in order to maintain continence while internal abdominal pressure rises the pelvic floor as to work in a precise trajectory, timing and force. observing the Urinary bladder by trans abdominal ultra sound (TAUS) was found as a valid and reliable way to estimate pelvic floor sagittal displacement and function.

NCT ID: NCT02930564 Terminated - Crohn's Disease Clinical Trials

The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

Start date: January 2017
Phase: N/A
Study type: Interventional

The Challenge study is a prospective, open label, pilot trial in patients in deep remission on dietary maintenance therapy. The purpose of this study is to determine whether they can consume some of the products that were eliminated from their diet, named the Crohn's Disease Exclusion Diet (CDED), and to evaluate if low dose exposure is harmful.